AbbVie’s shares rose 1.3%, a roughly flat reaction, as third-quarter revenue and adjusted EPS came in above the company’s expectations and full-year revenue guidance increased. Skyrizi and Rinvoq drove immunology growth, while the call also highlighted continued Humira sales declines.
AbbVie's shares declined 2.5% following Q2 earnings despite beatings in revenue and EPS, reflecting investor caution likely tied to ongoing biosimilar erosion in HUMIRA and mixed segment performance that tempered enthusiasm.
Shares rose 6.9% following AbbVie’s first quarter, as revenues, EPS, and commercial performance in key franchises decisively beat expectations. Management announced an upward revision to full-year EPS guidance and highlighted strong execution across immunology and neuroscience portfolios. The positive market reaction suggests investors were focused on upside in top and bottom line performance, robust commercial momentum, and the confident guidance raise.